Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | NSCLC | Review

PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells

Author: Meysam Moghbeli

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

Lung cancer, as the leading cause of cancer related deaths, is one of the main global health challenges. Despite various progresses in diagnostic and therapeutic methods, there is still a high rate of mortality among lung cancer patients, which can be related to the lack of clinical symptoms to differentiate lung cancer from the other chronic respiratory disorders in the early tumor stages. Most lung cancer patients are identified in advanced and metastatic tumor stages, which is associated with a poor prognosis. Therefore, it is necessary to investigate the molecular mechanisms involved in lung tumor progression and metastasis in order to introduce early diagnostic markers as well as therapeutic targets. Epithelial-mesenchymal transition (EMT) is considered as one of the main cellular mechanisms involved in lung tumor metastasis, during which tumor cells gain the metastatic ability by acquiring mesenchymal characteristics. Since, majority of the oncogenic signaling pathways exert their role in tumor cell invasion by inducing the EMT process, in the present review we discussed the role of PI3K/AKT signaling pathway in regulation of EMT process during lung tumor metastasis. It has been reported that the PI3K/AKT acts as an inducer of EMT process through the activation of EMT-specific transcription factors in lung tumor cells. MicroRNAs also exerted their inhibitory effects during EMT process by inhibition of PI3K/AKT pathway. This review can be an effective step towards introducing the PI3K/AKT pathway as a suitable therapeutic target to inhibit the EMT process and tumor metastasis in lung cancer patients.
Literature
1.
Sung WJ, Kim H, Park KK. The biological role of epithelial-mesenchymal transition in lung cancer (review). Oncol Rep. 2016;36(3):1199–206.PubMedCrossRef
2.
Avelino CU, Cardoso RM, Aguiar SS, Silva MJ. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. J Bras Pneumol. 2015;41(2):133–42.PubMedPubMedCentralCrossRef
3.
Chen HA, Chang YW, Tseng CF, Chiu CF, Hong CC, Wang W, et al. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer. Ann Surg Oncol. 2015;22(3):889–98.PubMedCrossRef
4.
Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1alpha destabilization. Mol Cancer. 2015;14:4.PubMedPubMedCentralCrossRef
5.
Maharati A, Zanguei AS, Khalili-Tanha G, Moghbeli M. MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Communication Signaling: CCS. 2022;20(1):27.PubMedPubMedCentralCrossRef
6.
Puisieux A, Brabletz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol. 2014;16(6):488–94.PubMedCrossRef
7.
Mahmoudian RA, Akhlaghipour I, Lotfi M, Shahidsales S, Moghbeli M. Circular RNAs as the pivotal regulators of epithelial-mesenchymal transition in gastrointestinal tumor cells. Pathol Res Pract. 2023;245:154472.PubMedCrossRef
8.
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.PubMedCrossRef
9.
Hamidi AA, Khalili-Tanha G, Nasrpour Navaei Z, Moghbeli M. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview. Cancer Cell Int. 2022;22(1):71.PubMedPubMedCentralCrossRef
10.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83.PubMedCrossRef
11.
Willis BC, Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L525–34.PubMedCrossRef
12.
Moghbeli M, Makhdoumi Y, Soltani Delgosha M, Aarabi A, Dadkhah E, Memar B, et al. ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer. Biol Res. 2019;52(1):2.PubMedPubMedCentralCrossRef
13.
Maharati A, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells. Cell Communication Signaling: CCS. 2023;21(1):201.PubMedPubMedCentralCrossRef
14.
Maharati A, Moghbeli M. Long non-coding RNAs as the critical regulators of PI3K/AKT, TGF-beta, and MAPK signaling pathways during breast tumor progression. J Transl Med. 2023;21(1):556.PubMedPubMedCentralCrossRef
15.
Chen M, Du Y, Qui M, Wang M, Chen K, Huang Z, et al. Ophiopogonin B-induced autophagy in non-small cell lung cancer cells via inhibition of the PI3K/Akt signaling pathway. Oncol Rep. 2013;29(2):430–6.PubMedCrossRef
16.
Alharbi KS, Shaikh MAJ, Almalki WH, Kazmi I, Al-Abbasi FA, Alzarea SI, et al. PI3K/Akt/mTOR pathways inhibitors with potential prospects in Non-small-cell Lung Cancer. J Environ Pathol Toxicol Oncology: Official Organ Int Soc Environ Toxicol Cancer. 2022;41(4):85–102.CrossRef
17.
Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag. 2014;3(1):67–75.PubMedCrossRef
18.
Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, et al. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep. 2017;7(1):7066.PubMedPubMedCentralCrossRef
19.
Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. Onco Targets Ther. 2016;9:203–10.PubMedPubMedCentralCrossRef
20.
21.
Navaei ZN, Khalili-Tanha G, Zangouei AS, Abbaszadegan MR, Moghbeli M. PI3K/AKT signaling pathway as a critical regulator of cisplatin response in tumor cells. Oncol Res. 2021;29(4):235–50.PubMedCrossRef
22.
23.
Kania A, Klein R. Mechanisms of ephrin-eph signalling in development, physiology and disease. Nat Rev Mol Cell Biol. 2016;17(4):240–56.PubMedCrossRef
24.
Yiminniyaze R, Zhang X, Zhu N, Wang J, Li C, Wumaier G, et al. EphrinA3 is a key regulator of malignant behaviors and a potential prognostic factor in lung adenocarcinoma. Cancer Med. 2023;12(2):1630–42.PubMedCrossRef
25.
Liu HY, Chang J, Li GD, Zhang ZH, Tian J, Mu YS. MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2020;24(11):6139–49.PubMed
26.
Sandhya VK, Raju R, Verma R, Advani J, Sharma R, Radhakrishnan A, et al. A network map of BDNF/TRKB and BDNF/p75NTR signaling system. J Cell Commun Signal. 2013;7(4):301–7.PubMedPubMedCentralCrossRef
27.
Li F, Wang X, Yang L. MicroRNA-147 targets BDNF to inhibit cell proliferation, migration and invasion in non-small cell lung cancer. Oncol Lett. 2020;20(2):1931–7.PubMedPubMedCentralCrossRef
28.
Cao S, Li L, Li J, Zhao H. MiR-1299 impedes the progression of Non-small-cell Lung Cancer through EGFR/PI3K/AKT signaling pathway. Onco Targets Ther. 2020;13:7493–502.PubMedPubMedCentralCrossRef
29.
Lu C, Shan Z, Hong J, Yang L. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Int J Oncol. 2017;51(1):235–44.PubMedCrossRef
30.
31.
Perez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, Garcia-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resist Updat. 2020;53:100718.PubMedCrossRef
32.
Toledo PL, Torkko JM, Muller A, Wegbrod C, Sonmez A, Solimena M, et al. ICA512 RESP18 homology domain is a protein-condensing factor and insulin fibrillation inhibitor. J Biol Chem. 2019;294(21):8564–76.PubMedPubMedCentralCrossRef
33.
Song X, Jiao X, Yan H, Yu L, Jiang L, Zhang M, et al. Overexpression of PTPRN promotes metastasis of lung adenocarcinoma and suppresses NK Cell cytotoxicity. Front Cell Dev Biol. 2021;9:622018.PubMedPubMedCentralCrossRef
34.
Yu H, Tian L, Yang L, Liu S, Wang S, Gong J. Knockdown of SNORA47 inhibits the tumorigenesis of NSCLC via Mediation of PI3K/Akt signaling pathway. Front Oncol. 2021;11:620213.PubMedPubMedCentralCrossRef
35.
36.
37.
Ibrahim DM, Shaaban ESE, Fouad TA. Circulating Resistin is Associated with plasma glucagon-like Peptide-1 in cirrhotic patients with Hepatitis C Virus Genotype-4 infection. Endocr Res. 2020;45(1):17–23.PubMedCrossRef
38.
Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, et al. Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int. 2011;108(2 Pt 2):E77–83.PubMed
39.
Zhao Y, Zheng R, Ning D, Xie F. MiR-625 inhibits Tumor Cell Invasion, Migration and EMT by negatively regulating the expression of Resistin in Non-small Cell Lung. Cancer Manag Res. 2020;12:4171–80.PubMedPubMedCentralCrossRef
40.
Jia Z, Zhang Y, Xu Q, Guo W, Guo A. miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncol Lett. 2018;15(5):7369–75.PubMedPubMedCentral
41.
Zhou F, Geng J, Xu S, Meng Q, Chen K, Liu F, et al. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. Aging. 2019;11(16):6069–88.PubMedPubMedCentralCrossRef
42.
Zhang J, Lu JP, Suter DM, Krause KH, Fini ME, Chen B, et al. Isoform- and dose-sensitive feedback interactions between paired box 6 gene and delta-catenin in cell differentiation and death. Exp Cell Res. 2010;316(6):1070–81.PubMedPubMedCentralCrossRef
43.
Zhang X, Yang X, Wang J, Liang T, Gu Y, Yang D. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer. Int J Clin Exp Pathol. 2015;8(9):11452–7.PubMedPubMedCentral
44.
Wu DM, Zhang T, Liu YB, Deng SH, Han R, Liu T, et al. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 2019;10(5):349.PubMedPubMedCentralCrossRef
45.
46.
Zhang Z, Wang Q, Chen F, Liu J. Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer. Tumour Biol. 2015;36(2):1213–9.PubMedCrossRef
47.
Zhong J, Liu C, Zhang QH, Chen L, Shen YY, Chen YJ, et al. TGF-beta1 induces HMGA1 expression: the role of HMGA1 in thyroid cancer proliferation and invasion. Int J Oncol. 2017;50(5):1567–78.PubMedPubMedCentralCrossRef
48.
Ma Y, Li X, Chen S, Du B, Li Y. MicroRNA-4458 suppresses migration and epithelial-mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells. Cancer Manag Res. 2019;11:637–49.PubMedPubMedCentralCrossRef
49.
Qi L, Zhang Y. Truncation of inhibitor of growth family protein 5 effectively induces senescence, but not apoptosis in human tongue squamous cell carcinoma cell line. Tumour Biol. 2014;35(4):3139–44.PubMedCrossRef
50.
Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, Okamura S, et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003;63(10):2373–8.PubMed
51.
Liu XL, Zhang XT, Meng J, Zhang HF, Zhao Y, Li C, et al. ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget. 2017;8(33):54265–76.PubMedPubMedCentralCrossRef
52.
Sauve AA, Wolberger C, Schramm VL, Boeke JD. The biochemistry of sirtuins. Annu Rev Biochem. 2006;75:435–65.PubMedCrossRef
53.
Cai D, Li J, Liu D, Hong S, Qiao Q, Sun Q, et al. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cell Mol Immunol. 2020;17(3):227–36.PubMedCrossRef
54.
Yu TT, Zhang T, Lu X, Wang RZ. B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther. 2018;11:4693–700.PubMedPubMedCentralCrossRef
55.
Liao H, Ding M, Zhou N, Yang Y, Chen L. B7–H3 promotes the epithelial–mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol Med Rep. 2022;25(3).
56.
Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, Xia XF, et al. Hypoxia-Induced epithelial-to-mesenchymal transition in Hepatocellular Carcinoma induces an immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Res. 2016;76(4):818–30.PubMedCrossRef
57.
Dominici C, Moreno-Bravo JA, Puiggros SR, Rappeneau Q, Rama N, Vieugue P, et al. Floor-plate-derived netrin-1 is dispensable for commissural axon guidance. Nature. 2017;545(7654):350–4.PubMedPubMedCentralCrossRef
58.
Akino T, Han X, Nakayama H, McNeish B, Zurakowski D, Mammoto A, et al. Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma. Cancer Res. 2014;74(14):3716–26.PubMedPubMedCentralCrossRef
59.
Zhang Y, Wang B, Chen X, Li W, Dong P. AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells. Oncotarget. 2017;8(33):54735–46.PubMedPubMedCentralCrossRef
60.
Jin X, Luan H, Chai H, Yan L, Zhang J, Wang Q, et al. Netrin–1 interference potentiates epithelial–to–mesenchymal transition through the PI3K/AKT pathway under the hypoxic microenvironment conditions of non–small cell lung cancer. Int J Oncol. 2019;54(4):1457–65.PubMed
61.
Xu X, Zhou X, Gao C, Cui Y. Hsa_circ_0018818 knockdown suppresses tumorigenesis in non-small cell lung cancer by sponging miR-767-3p. Aging. 2020;12(9):7774–85.PubMedPubMedCentralCrossRef
62.
Wang B, Yang X, Zhao T, Du H, Wang T, Zhong S, et al. Upregulation of contactin-1 expression promotes prostate cancer progression. Oncol Lett. 2020;19(2):1611–8.PubMed
63.
64.
Hu CS, Huang JH, Yang DL, Xu C, Xu ZG, Tan HB, et al. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells. Oncol Lett. 2021;21(6):433.PubMedPubMedCentralCrossRef
65.
Yu T, Guo Z, Fan H, Song J, Liu Y, Gao Z, et al. Cancer-associated fibroblasts promote non-small cell lung cancer cell invasion by upregulation of glucose-regulated protein 78 (GRP78) expression in an integrated bionic microfluidic device. Oncotarget. 2016;7(18):25593–603.PubMedPubMedCentralCrossRef
66.
Qiu X, Guan X, Liu W, Zhang Y. DAL-1 attenuates epithelial to mesenchymal transition and metastasis by suppressing HSPA5 expression in non-small cell lung cancer. Oncol Rep. 2017;38(5):3103–13.PubMedCrossRef
67.
Qiu YS, Jiang NN, Zhou Y, Yu KY, Gong HY, Liao GJ. LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3beta signaling. Int J Mol Med. 2018;41(5):2755–63.PubMedPubMedCentral
68.
Larsen S, Yokochi T, Isogai E, Nakamura Y, Ozaki T, Nakagawara A. LMO3 interacts with p53 and inhibits its transcriptional activity. Biochem Biophys Res Commun. 2010;392(3):252–7.PubMedCrossRef
69.
Xuan YW, Liao M, Zhai WL, Peng LJ, Tang Y. MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. Eur Rev Med Pharmacol Sci. 2019;23(19):8411–21.PubMed
70.
Tang Z, Ding Y, Shen Q, Zhang C, Li J, Nazar M, et al. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT. J Mol Med (Berl). 2019;97(1):127–40.PubMedCrossRef
71.
Wang S, Wu Y, Yang S, Liu X, Lu Y, Liu F, et al. miR-874 directly targets AQP3 to inhibit cell proliferation, mobility and EMT in non-small cell lung cancer. Thorac Cancer. 2020;11(6):1550–8.PubMedPubMedCentralCrossRef
72.
Sutton KA, Jungnickel MK, Wang Y, Cullen K, Lambert S, Florman HM. Enkurin is a novel calmodulin and TRPC channel binding protein in sperm. Dev Biol. 2004;274(2):426–35.PubMedCrossRef
73.
Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: the 1996 guide for the Care and Use of Laboratory animals. ILAR J. 1997;38(1):41–8.PubMedCrossRef
74.
Ma Q, Lu Y, Lin J, Gu Y. ENKUR acts as a tumor suppressor in lung adenocarcinoma cells through PI3K/Akt and MAPK/ERK signaling pathways. J Cancer. 2019;10(17):3975–84.PubMedPubMedCentralCrossRef
75.
Saiprasad G, Chitra P, Manikandan R, Sudhandiran G. Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogenesis. Eur J Cancer. 2014;50(14):2489–507.PubMedCrossRef
76.
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu C, et al. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3beta/beta-catenin pathways. Mol Cancer. 2017;16(1):70.PubMedPubMedCentralCrossRef
77.
Zhou SL, Zhou ZJ, Hu ZQ, Li X, Huang XW, Wang Z, et al. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling. Cancer Lett. 2015;358(2):124–35.PubMedCrossRef
78.
Neve RM, Parmar H, Amend C, Chen C, Rizzino A, Benz CC. Identification of an epithelial-specific enhancer regulating ESX expression. Gene. 2006;367:118–25.PubMedCrossRef
79.
Oliver JR, Kushwah R, Hu J. Multiple roles of the epithelium-specific ETS transcription factor, ESE-1, in development and disease. Lab Invest. 2012;92(3):320–30.PubMedCrossRef
80.
Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J, et al. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 2018;94:98–106.PubMedCrossRef
81.
Malovannaya A, Lanz RB, Jung SY, Bulynko Y, Le NT, Chan DW, et al. Analysis of the human endogenous coregulator complexome. Cell. 2011;145(5):787–99.PubMedPubMedCentralCrossRef
82.
Li M, Liu Z, Hou Z, Wang X, Shi H, Li Y, et al. Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway. Thorac Cancer. 2023;14(14):1223–38.PubMedPubMedCentralCrossRef
83.
Barcellos KS, Bigarella CL, Wagner MV, Vieira KP, Lazarini M, Langford PR, et al. ARHGAP21 protein, a new partner of alpha-tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition. J Biol Chem. 2013;288(4):2179–89.PubMedCrossRef
84.
Basseres DS, Tizzei EV, Duarte AA, Costa FF, Saad ST. ARHGAP10, a novel human gene coding for a potentially cytoskeletal Rho-GTPase activating protein. Biochem Biophys Res Commun. 2002;294(3):579–85.PubMedCrossRef
85.
Lin LL, Yang F, Zhang DH, Hu C, Yang S, Chen XQ. ARHGAP10 inhibits the epithelial-mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3beta signaling pathway. Cancer Cell Int. 2021;21(1):320.PubMedPubMedCentralCrossRef
86.
Lu LY, Wu J, Ye L, Gavrilina GB, Saunders TL, Yu X. RNF8-dependent histone modifications regulate nucleosome removal during spermatogenesis. Dev Cell. 2010;18(3):371–84.PubMedPubMedCentralCrossRef
87.
Kuang J, Li L, Guo L, Su Y, Wang Y, Xu Y, et al. RNF8 promotes epithelial-mesenchymal transition of breast cancer cells. J Exp Clin Cancer Res. 2016;35(1):88.PubMedPubMedCentralCrossRef
88.
Kuang J, Min L, Liu C, Chen S, Gao C, Ma J, et al. RNF8 promotes epithelial-mesenchymal transition in Lung Cancer cells via stabilization of slug. Mol Cancer Res. 2020;18(11):1638–49.PubMedCrossRef
89.
Duan Z, Gao B, Xu W, Xiong S. Identification of TRIM22 as a RING finger E3 ubiquitin ligase. Biochem Biophys Res Commun. 2008;374(3):502–6.PubMedCrossRef
90.
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu XJ, et al. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3beta/beta-catenin signaling in non-small cell lung cancer. Oncotarget. 2017;8(37):62069–80.PubMedPubMedCentralCrossRef
91.
Moghbeli M, Mosannen Mozaffari H, Memar B, Forghanifard MM, Gholamin M, Abbaszadegan MR. Role of MAML1 in targeted therapy against the esophageal cancer stem cells. J Transl Med. 2019;17(1):126.PubMedPubMedCentralCrossRef
92.
Chang M, Jin W, Chang JH, Xiao Y, Brittain GC, Yu J, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12(10):1002–9.PubMedPubMedCentralCrossRef
93.
Chang M, Jin W, Sun SC. Peli1 facilitates TRIF-dependent toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol. 2009;10(10):1089–95.PubMedPubMedCentralCrossRef
94.
Jeon YK, Kim CK, Hwang KR, Park HY, Koh J, Chung DH, et al. Pellino-1 promotes lung carcinogenesis via the stabilization of slug and snail through K63-mediated polyubiquitination. Cell Death Differ. 2017;24(3):469–80.PubMedCrossRef
95.
Saeki K, Nose Y, Hirao N, Takasawa R, Tanuma S. Amyloid precursor protein binding protein Fe65 is cleaved by caspases during DNA damage-induced apoptosis. Biol Pharm Bull. 2011;34(2):290–4.PubMedCrossRef
96.
Haisa M. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. J Int Med Res. 2013;41(2):253–64.PubMedCrossRef
97.
Lee JH, Kim JY, Kim SY, Choi SI, Kim KC, Cho EW, et al. APBB1 reinforces cancer stem cell and epithelial-to-mesenchymal transition by regulating the IGF1R signaling pathway in non-small-cell lung cancer cells. Biochem Biophys Res Commun. 2017;482(1):35–42.PubMedCrossRef
98.
99.
Yuan Y, Liao H, Pu Q, Ke X, Hu X, Ma Y, et al. miR-410 induces both epithelial-mesenchymal transition and radioresistance through activation of the PI3K/mTOR pathway in non-small cell lung cancer. Signal Transduct Target Ther. 2020;5(1):85.PubMedPubMedCentralCrossRef
100.
Khandelwal A, Sharma U, Barwal TS, Seam RK, Gupta M, Rana MK, et al. Circulating miR-320a acts as a tumor suppressor and prognostic factor in non-small cell Lung Cancer. Front Oncol. 2021;11:645475.PubMedPubMedCentralCrossRef
101.
Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, Batzler AJ, et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res. 2011;17(17):5801–11.PubMedPubMedCentralCrossRef
102.
Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31(2):277–83.PubMed
103.
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012;31(4):432–45.PubMedCrossRef
104.
Chen QY, Jiao DM, Wang J, Hu H, Tang X, Chen J, et al. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 2016;7(17):24510–26.PubMedPubMedCentralCrossRef
105.
Wang YL, Yao WJ, Guo L, Xi HF, Li SY, Wang ZM. Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 2015;8(1):601–7.PubMedPubMedCentral
106.
Mou X, Liu S. MiR-485 inhibits metastasis and EMT of lung adenocarcinoma by targeting Flot2. Biochem Biophys Res Commun. 2016;477(4):521–6.PubMedCrossRef
107.
Fakhrejahani E, Toi M. Tumor angiogenesis: pericytes and maturation are not to be ignored. J Oncol. 2012;2012:261750.PubMedCrossRef
108.
Griffioen AW. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends Cardiovasc Med. 2007;17(5):171–6.PubMedCrossRef
109.
Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33(6):679–89.PubMedCrossRef
110.
Gao D, Vahdat LT, Wong S, Chang JC, Mittal V. Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. Cancer Res. 2012;72(19):4883–9.PubMedPubMedCentralCrossRef
111.
Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008;27(1):85–94.PubMedCrossRef
112.
Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012;31(3–4):455–67.PubMedCrossRef
113.
Chen QY, Jiao DM, Wu YQ, Chen J, Wang J, Tang XL, et al. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway. Oncotarget. 2016;7(14):18247–61.PubMedPubMedCentralCrossRef
114.
Tanaka S, Sakaguchi M, Yoneyama H, Usami Y, Harusawa S, Histamine. H(3) receptor antagonist OUP-186 attenuates the proliferation of cultured human breast cancer cell lines. Biochem Biophys Res Commun. 2016;480(3):479–85.PubMedCrossRef
115.
Bongers G, Bakker RA, Leurs R. Molecular aspects of the histamine H3 receptor. Biochem Pharmacol. 2007;73(8):1195–204.PubMedCrossRef
116.
Zhao YY, Jia J, Zhang JJ, Xun YP, Xie SJ, Liang JF, et al. Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT. Acta Pharmacol Sin. 2021;42(8):1288–97.PubMedCrossRef
117.
Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 2009;1790(11):1555–68.PubMedCrossRef
118.
119.
Wingler K, Muller C, Schmehl K, Florian S, Brigelius-Flohe R. Gastrointestinal glutathione peroxidase prevents transport of lipid hydroperoxides in CaCo-2 cells. Gastroenterology. 2000;119(2):420–30.PubMedCrossRef
120.
Peng F, Xu Q, Jing X, Chi X, Zhang Z, Meng X, et al. GPX2 promotes EMT and metastasis in non-small cell lung cancer by activating PI3K/AKT/mTOR/Snail signaling axis. FASEB Bioadv. 2023;5(6):233–50.PubMedPubMedCentralCrossRef
Metadata
Title
PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells
Author
Meysam Moghbeli
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-024-03357-7

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Smad2/3/4 complex could undergo liquid liquid phase separation and induce apoptosis through TAT in hepatocellular carcinoma

Review

Altering phosphorylation in cancer through PP2A modifiers

Research

Upregulation of TTK expression is associated with poor prognosis and immune infiltration in endometrial cancer patients

Research

Identification of fatty acids synthesis and metabolism-related gene signature and prediction of prognostic model in hepatocellular carcinoma

Review

Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications

Research

The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitntriors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits